SEC Form 4
Cytokinetics Inc. (CYTK) insider trading
In the 12 months to Oct 26, 2026, 10 CYTK insiders reported open-market sales of $47.4M across 71 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $47.4M
- 71 filings · 10 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 71 of 71
- All $47.4M sold was pre-arranged
Who traded CYTK, and when
- Sale
- Sale, pre-arranged (10b5-1)
CYTK daily close from Oct 27, 2025 to Oct 26, 2026, between $59.19 and $87.26, last $60.96. 71 sale and 0 purchase filings by 10 insiders, marked at their filing dates. Andrew Callos, EVP, Chief Commercial Officer: sold $15.3M across 20 filings, first filed Dec 5, 2025, last Aug 31, 2026. Robert I. Blum, President & CEO: sold $14.7M across 15 filings, first filed Oct 30, 2025, last Oct 13, 2026. Sung Lee, EVP, Chief Financial Officer: sold $5.4M across 4 filings, first filed May 5, 2026, last Jul 2, 2026. Fady Ibraham Malik, EVP Research & Development: sold $3.9M across 17 filings, first filed Nov 4, 2025, last Oct 20, 2026. Edward M. MD Kaye, Director: sold $2.4M across 3 filings, first filed Nov 12, 2025, last Jun 1, 2026. John T. Henderson, Director: sold $2.1M across 2 filings, first filed Dec 2, 2025, last May 5, 2026. 4 others: sold $3.5M across 10 filings, first filed Oct 27, 2025, last Sep 15, 2026.
Largest mark · tap a row for others
Robert I. Blum · President & CEO
Sale $7,340,010
105,426 shares at $69.62 avg
Filed Sep 15, 2026 · traded Sep 14
Pre-arranged (10b5-1) · close on filing date $69.31
Andrew Callos · EVP, Chief Commercial Officer
EVP, Chief Commercial Officer
$15.3M soldRobert I. Blum · President & CEO
President & CEO
$14.7M soldSung Lee · EVP, Chief Financial Officer
EVP, Chief Financial Officer
$5.4M soldFady Ibraham Malik · EVP Research & Development
EVP Research & Development
$3.9M soldEdward M. MD Kaye · Director
Director
$2.4M soldJohn T. Henderson · Director
Director
$2.1M sold4 others
Combined, one mark per week
$3.5M soldOpen-market trades
71 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Andrew Callos | EVP, Chief Commercial Officer | $15.3M | — | 20 | 100% of sales | |
| Robert I. Blum | President & CEO | $14.7M | — | 15 | 100% of sales | |
| Sung Lee | EVP, Chief Financial Officer | $5.4M | — | 4 | 100% of sales | |
| Fady Ibraham Malik | EVP Research & Development | $3.9M | — | 17 | 100% of sales | |
| Edward M. MD Kaye | Director | $2.4M | — | 3 | 100% of sales | |
| John T. Henderson | Director | $2.1M | — | 2 | 100% of sales | |
| Wendell Wierenga | Director | $1.9M | — | 3 | 100% of sales | |
| B. Lynne Parshall | Director | $1.4M | — | 4 | 100% of sales | |
| Robert E. Landry | Director | $146.8K | — | 2 | 100% of sales | |
| Robert Arthur Harrington | Director | $143.6K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $64.01 | $224.0K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $62.88 | $471.6K | 278,544 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $61.38 | $214.8K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $65.46 | $490.9K | 278,544 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $68.29 | $239.0K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 105,426 | $69.62 | $7.3M | Multiple accounts | |
traded | Robert E. Landry Director | SalePre-arranged (10b5-1) | 1,000 | $72.13 | $72.1K | 8,184 | |
traded | Robert E. Landry Director | SalePre-arranged (10b5-1) | 1,000 | $74.66 | $74.7K | 9,184 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $75.46 | $264.1K | 153,902 | |
traded | B. Lynne Parshall Director | SalePre-arranged (10b5-1) | 5,000 | $71.48 | $357.4K | 10,784 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $70.24 | $526.8K | 377,820 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 10,000 | $70.24 | $702.4K | 58,555 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $75.82 | $265.4K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $76.76 | $575.7K | 377,820 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 14,000 | $79.88 | $1.1M | 58,555 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $80.87 | $606.5K | 377,820 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $80.59 | $282.1K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $82.02 | $615.1K | 377,820 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $86.62 | $303.2K | 153,902 | |
traded | Sung Lee EVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 1,112 | $87.79 | $97.6K | 63,221 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 15,000 | $85.80 | $1.3M | 58,555 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $84.92 | $636.9K | 377,830 | |
traded | Sung Lee EVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 3,134 | $85.00 | $266.4K | 63,221 | |
traded | Sung Lee EVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 38,730 | $82.30 | $3.2M | 63,221 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $79.51 | $278.3K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $70.46 | $528.5K | 385,330 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $67.98 | $237.9K | 153,902 | |
traded | B. Lynne Parshall Director | SalePre-arranged (10b5-1) | 5,000 | $74.08 | $370.4K | 15,784 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 15,000 | $74.08 | $1.1M | 58,555 | |
traded | Edward M. MD Kaye Director | SalePre-arranged (10b5-1) | 2,933 | $76.09 | $223.2K | 10,283 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $77.21 | $579.1K | 392,830 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $75.69 | $264.9K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $77.92 | $584.4K | 400,330 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 11,333 | $77.25 | $875.5K | 58,555 | |
traded | John T. Henderson Director | SalePre-arranged (10b5-1) | 20,000 | $75.97 | $1.5M | 75,237 | |
traded | Sung Lee EVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 23,906 | $76.87 | $1.8M | 63,221 | |
traded | Wendell Wierenga Director | SalePre-arranged (10b5-1) | 4,032 | $75.00 | $302.4K | 32,637 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $77.37 | $270.8K | 153,902 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 15,857 | $65.00 | $1.0M | 58,555 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 15,000 | $63.26 | $948.9K | 58,555 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $59.62 | $447.2K | 407,830 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 3,500 | $65.69 | $229.9K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $65.38 | $490.3K | 415,330 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 7,449 | $66.02 | $491.8K | 58,555 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 4,500 | $65.11 | $293.0K | 153,902 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 7,500 | $66.63 | $499.7K | 422,830 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 3,639 | $65.00 | $236.5K | 66,004 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 1,930 | $62.07 | $119.8K | 78,185 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 1,709 | $61.03 | $104.3K | 46,149 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 26,000 | $61.87 | $1.6M | 61,440 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 886 | $61.62 | $54.6K | 50,440 | |
traded | B. Lynne Parshall Director | SalePre-arranged (10b5-1) | 5,000 | $61.21 | $306.1K | 17,933 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 15,000 | $61.93 | $929.0K | 50,440 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 886 | $62.10 | $55.0K | 50,440 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 15,000 | $60.28 | $904.2K | 50,440 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 1,798 | $62.62 | $112.6K | 50,440 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 1,809 | $62.44 | $113.0K | 51,353 | |
traded | Wendell Wierenga Director | SalePre-arranged (10b5-1) | 20,000 | $66.14 | $1.3M | 32,444 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 2,200 | $61.24 | $134.7K | 138,552 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 1,042 | $65.96 | $68.7K | 50,660 | |
traded | Andrew Callos EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 52,486 | $65.95 | $3.5M | 50,660 | |
traded | Robert Arthur Harrington Director | SalePre-arranged (10b5-1) | 2,150 | $66.80 | $143.6K | 18,542 | |
traded | Edward M. MD Kaye Director | SalePre-arranged (10b5-1) | 28,064 | $66.72 | $1.9M | 9,977 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 2,200 | $63.89 | $140.6K | 140,610 | |
traded | John T. Henderson Director | SalePre-arranged (10b5-1) | 8,750 | $63.90 | $559.1K | 74,578 | |
traded | B. Lynne Parshall Director | SalePre-arranged (10b5-1) | 5,000 | $64.73 | $323.7K | 22,933 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 2,200 | $66.45 | $146.2K | 140,610 | |
traded | Edward M. MD Kaye Director | SalePre-arranged (10b5-1) | 5,175 | $65.08 | $336.8K | 9,977 | |
traded | Fady Ibraham Malik EVP Research & Development | SalePre-arranged (10b5-1) | 2,295 | $59.55 | $136.7K | 140,610 | |
traded | Robert I. Blum President & CEO | SalePre-arranged (10b5-1) | 5,000 | $62.86 | $314.3K | 358,108 | |
traded | Wendell Wierenga Director | SalePre-arranged (10b5-1) | 4,375 | $58.68 | $256.7K | 32,444 |
GET /stocks/filings/vX/form-4?tickers=CYTK&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CYTK"
],
"issuer_cik": "0001061983",
"owner_cik": "0001551778",
"accession_number": "0001061983-26-000100",
"form_type": "4",
"filing_date": "2026-10-20",
"period_of_report": "2026-10-20",
"issuer_name": "CYTOKINETICS INC",
"issuer_trading_symbol": "CYTK",
"owner_name": "Malik Fady Ibraham",
"is_officer": true,
"officer_title": "EVP Research & Development",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 3500,
"transaction_price_per_share": 64.01,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 153902,
"transaction_value": 224035.00000000003,
"direct_or_indirect": "D"
},
{
"tickers": [
"CYTK"
],
"issuer_cik": "0001061983",
"owner_cik": "0001288859",
"accession_number": "0001061983-26-000099",
"form_type": "4",
"filing_date": "2026-10-13",
"period_of_report": "2026-10-12",
"issuer_name": "CYTOKINETICS INC",
"issuer_trading_symbol": "CYTK",
"owner_name": "Blum Robert I",
"is_director": true,
"is_officer": true,
"officer_title": "President & CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-12",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 7500,
"transaction_price_per_share": 62.88,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 278544,
"transaction_value": 471600,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 138 records
- Option exercises67 records
- Tax withholding9 records
- Tax withholding (sold to cover)10 records
- Grants and awards48 records
- Gifts4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Cytokinetics Inc.'s CEO sold stock?
Yes. Robert I. Blum (CEO) sold 207,926 shares ($14.7M) between Oct 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan.
How current is CYTK’s insider data?
These are CYTK Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track CYTK insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CYTK every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.